ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailPositive ArrowIcon PrintIcon Twitter
Health Technology

Healios KK

Business Summary

Healios KK engages in the research, development, and sale of cellular and regenerative medicine. It develops therapies for ischemic stroke, acute respiratory distress syndrome, liver disease, and age-regulated macular degeneration. The company was founded by Tadahisa Kagimoto on February 24, 2011 and is headquartered in Tokyo, Japan.

Financial Highlights

Dec 2020 JPYUSD
Revenue27M0.25M
Gross Profit----
Operating income-4,198M-39.31M
Income before tax-5,364M-50.23M
Net income-5,512M-51.62M
EBITDA-3,969M-37.17M
Diluted EPS-107.19-1.00
Dividends Per Share00
Total Assets23,171M224.42M
Total liabilities15,320M148.38M
Total equity7,844M75.97M
Operating cash flow-3,945M-36.94M
Currency in JPYCurrency in USD

Historical Data

 Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020
Revenue 77.64M 27.66M 0 89M 27M
Gross Profit -100.81M -75.96M -78M -- --
Operating income -3,507.46M -2,348.20M -5,063M -4,281M -4,198M
Income before tax -3,426.74M -1,771.55M -5,091M -4,547M -5,364M
Net income -3,433.55M -1,776.65M -5,097M -4,806M -5,512M
EBITDA -3,338.15M -2,247.89M -4,985M -4,140M -3,969M
Diluted EPS -84.33 -39.73 -103.51 -95.85 -107.19
Dividends Per Share 0 0 0 0 0
Total Assets 9,174.98M 19,696.42M 14,980M 25,594M 23,171M
Total liabilities 3,180.55M 3,532.74M 4,196M 13,250M 15,320M
Total equity 5,994.42M 16,163.67M 10,782M 12,335M 7,844M
Operating cash flow -3,782.67M -1,762.18M -5,148M -4,859M -3,945M
 Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020
Revenue 0.71M 0.24M 0 0.81M 0.25M
Gross Profit -0.92M -0.67M -0.70M -- --
Operating income -32.27M -20.94M -45.84M -39.27M -39.31M
Income before tax -31.53M -15.79M -46.09M -41.71M -50.23M
Net income -31.59M -15.84M -46.15M -44.08M -51.62M
EBITDA -30.72M -20.04M -45.13M -37.97M -37.17M
Diluted EPS -0.77 -0.35 -0.93 -0.87 -1.00
Dividends Per Share 0 0 0 0 0
Total Assets 78.66M 174.84M 136.53M 235.50M 224.42M
Total liabilities 27.26M 31.36M 38.24M 121.92M 148.38M
Total equity 51.39M 143.48M 98.27M 113.50M 75.97M
Operating cash flow -34.81M -15.71M -46.61M -44.57M -36.94M

Valuation Measures

Dec 2020
PER--
ROA-22.60%
ROE-54.63%
Operating margin-15,548.14%
Profit margin-20,414.81%

Key executives

  • President, Chief Executive Officer & Director: Hardy T. S. Kagimoto
  • Chief Financial Officer & Director: Richard Patrick Kincaid
  • Chief Medical Officer & Executive Vice President: Masanori Sawada
  • Executive Officer, Head-Research & Production Area: Kouichi Tamura
  • Executive Officer & Head-Development Area: Michihisa Nishiyama

Shareholders

  • KAGIMOTO HARDY T S (51.4%)
  • Baillie Gifford & Co. (6.3%)
  • JPMorgan Asset Management (Japan) Ltd. (4.6%)
  • Nikon Corp. (2.7%)
  • Sumitomo Dainippon Pharma Co., Ltd. (2.7%)
  • Matthews International Capital Management LLC (2.2%)
  • FUJIOKA YOSHIHISA (1.1%)
  • Asset Management One Co., Ltd. (0.8%)
  • FIL Investment Management (Hong Kong) Ltd. (0.7%)
  • MATSUDA YOSHINARI (0.5%)

Contact Details

Related Companies

  • Healios N.A., Inc.
  • Sighregen Co., Ltd.

Competitors

    Last Updated on 3 Dec, 2021

    Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.

    Celebrate our next chapter
    Free access for everyone - Sep. 30

    Find out more